Personalized Medicine Will Require Greater CDER, CDRH Cooperation
Drug regulation during an era of personalized medicine will require cultural if not structural changes on the part of FDA
You may also be interested in...
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.